Introduction: Chronic myeloid leukaemia (CML) is a myeloproliferative neoplasm characterized by constitutive activity of the tyrosine kinase BCR-ABL1. Drug resistance remains one of the major challenges in CML therapy. MicroRNA (miR)-199a-3p plays an important role in many tumours but has rarely been investigated in CML. We aimed to analyse the role and mechanism of miR-199a-3p in regulating imatinib resistance in CML. Methods: The expression of miR-199a-3p and mammalian target of rapamycin (mTOR) in the serum of CML patients and CML cells was examined by quantitative real-time polymerase chain reaction. The levels of apoptosis-related proteins were determined using western blot. The relative cell survival rate and cell proliferation were determined using a CCK-8 assay and a bromodeoxyuridine (BrdU) assay, respectively. Cell cycle and apoptosis were analysed using flow cytometry. Moreover, a dual-luciferase reporter assay was performed to verify the correlation between miR-199a-3p and mTOR. Results: MiR-199a-3p was downregulated in the serum of CML patients and in CML cells, while mTOR was upregulated. Both miR-199a-3p overexpression and mTOR silencing inhibited CML cell proliferation, promoted CML cell apoptosis, and sensitized these cells to imatinib. mTOR silencing reversed the promoting effect of miR-199a-3p inhibition on the proliferation of CML cells and the inhibitory effects on cell apoptosis and sensitivity to imatinib. MiR-199a-3p directly targeted mTOR. Conclusion: MiR-199a-3p suppressed cell propagation, facilitated apoptosis of CML cells, and sensitized CML cells to imatinib by downregulating mTOR signalling.

1.
Rowley
JD
.
Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and giemsa staining
.
Nature
.
1973
;
243
(
5405
):
290
3
. .
2.
Apperley
JF
.
Chronic myeloid leukaemia
.
Lancet
.
2015
;
385
(
9976
):
1447
59
. .
3.
Jabbour
E
,
Kantarjian
H
.
Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring
.
Am J Hematol
.
2018
;
93
(
3
):
442
59
. .
4.
Wagle
M
,
Eiring
AM
,
Wongchenko
M
,
Lu
S
,
Guan
Y
,
Wang
Y
,
A role for FOXO1 in BCR-ABL1-independent tyrosine kinase inhibitor resistance in chronic myeloid leukemia
.
Leukemia
.
2016
;
30
(
7
):
1493
501
.
5.
Wang
T
,
Wen
T
,
Li
H
,
Han
B
,
Hao
S
,
Wang
C
,
Arsenic sulfide nanoformulation induces erythroid differentiation in chronic myeloid leukemia cells through degradation of BCR-ABL
.
Int J Nanomed
.
2019
;
14
:
5581
94
.
6.
Lan
X
,
Zhao
C
,
Chen
X
,
Zhang
P
,
Zang
D
,
Wu
J
,
Nickel pyrithione induces apoptosis in chronic myeloid leukemia cells resistant to imatinib via both Bcr/Abl-dependent and Bcr/Abl-independent mechanisms
.
J Hematol Oncol
.
2016
;
9
(
1
):
129
.
7.
García-Gutiérrez
V
,
Hernández-Boluda
JC
.
Tyrosine kinase inhibitors available for chronic myeloid leukemia: efficacy and safety
.
Front Oncol
.
2019
;
9
:
603
.
8.
Pasic
I
,
Lipton
JH
.
Current approach to the treatment of chronic myeloid leukaemia
.
Leuk Res
.
2017
;
55
:
65
78
. .
9.
Bixby
D
,
Talpaz
M
.
Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistance
.
Hematology Am Soc Hematol Educ Program
.
2009
:
461
76
. .
10.
Holyoake
TL
,
Vetrie
D
.
The chronic myeloid leukemia stem cell: stemming the tide of persistence
.
Blood
.
2017
;
129
(
12
):
1595
606
. .
11.
Mitchell
R
,
Hopcroft
LEM
,
Baquero
P
,
Allan
EK
,
Hewit
K
,
James
D
,
Targeting BCR-ABL-independent TKI resistance in chronic myeloid leukemia by mTOR and autophagy inhibition
.
J Natl Cancer Inst
.
2018
;
110
(
5
):
467
78
.
12.
Breccia
M
,
Alimena
G
.
How to treat CML patients in the tyrosine kinase inhibitors era? From imatinib standard dose to second generation drugs front-line: unmet needs, pitfalls and advantages
.
Cancer Lett
.
2012
;
322
(
2
):
127
32
. .
13.
Zhang
Y
,
Huang
B
,
Wang
HY
,
Chang
A
,
Zheng
XFS
.
Emerging role of microRNAs in mTOR signaling
.
Cell Mol Life Sci
.
2017
;
74
(
14
):
2613
25
. .
14.
Salunkhe
S
,
Vaidya
T
.
CD40-miRNA axis controls prospective cell fate determinants during B cell differentiation
.
Mol Immunol
.
2020
;
126
:
46
55
. .
15.
Hershkovitz-Rokah
O
,
Modai
S
,
Pasmanik-Chor
M
,
Toren
A
,
Shomron
N
,
Raanani
P
,
Restoration of miR-424 suppresses BCR-ABL activity and sensitizes CML cells to imatinib treatment
.
Cancer Lett
.
2015
;
360
(
2
):
245
56
.
16.
Ma
J
,
Wu
D
,
Yi
J
,
Yi
Y
,
Zhu
X
,
Qiu
H
,
MiR-378 promoted cell proliferation and inhibited apoptosis by enhanced stem cell properties in chronic myeloid leukemia K562 cells
.
Biomed Pharmacother
.
2019
;
112
:
108623
.
17.
Cao
HX
,
Miao
CF
,
Sang
LN
,
Huang
YM
,
Zhang
R
,
Sun
L
,
Circ_0009910 promotes imatinib resistance through ULK1-induced autophagy by sponging miR-34a-5p in chronic myeloid leukemia
.
Life Sci
.
2020
;
243
:
117255
.
18.
Sun
Y
,
Ma
G
,
Xiang
H
,
Wang
X
,
Wang
H
,
Zhang
Y
,
circFLNA promotes glioblastoma proliferation and invasion by negatively regulating miR-199-3p expression
.
Mol Med Rep
.
2021
;
24
(
5
):
786
.
19.
Giovannini
C
,
Fornari
F
,
Dallo
R
,
Gagliardi
M
,
Nipoti
E
,
Vasuri
F
,
MiR-199-3p replacement affects E-cadherin expression through notch1 targeting in hepatocellular carcinoma
.
Acta Histochemica
.
2018
;
120
(
2
):
95
102
.
20.
Luna-Aguirre
CM
,
de la Luz Martinez-Fierro
M
,
Mar-Aguilar
F
,
Garza-Veloz
I
,
Treviño-Alvarado
V
,
Rojas-Martinez
A
,
Circulating microRNA expression profile in B-cell acute lymphoblastic leukemia
.
Cancer Biomark
.
2015
;
15
(
3
):
299
310
.
21.
Shi
H
,
Li
XY
,
Chen
Y
,
Zhang
X
,
Wu
Y
,
Wang
ZX
,
Quercetin induces apoptosis via downregulation of vascular endothelial growth factor/Akt signaling pathway in acute myeloid leukemia cells
.
Front Pharmacol
.
2020
;
11
:
534171
.
22.
Cotoraci
C
,
Ciceu
A
,
Sasu
A
,
Miutescu
E
,
Hermenean
A
.
The anti-leukemic activity of natural compounds
.
Molecules
.
2021
;
26
(
9
):
2709
.
23.
Gorre
ME
,
Mohammed
M
,
Ellwood
K
,
Hsu
N
,
Paquette
R
,
Rao
PN
,
Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification
.
Science
.
2001
;
293
(
5531
):
876
80
.
24.
Wen
F
,
Cao
YX
,
Luo
ZY
,
Liao
P
,
Lu
ZW
.
LncRNA MALAT1 promotes cell proliferation and imatinib resistance by sponging miR-328 in chronic myelogenous leukemia
.
Biochem Biophys Res Commun
.
2018
;
507
(
1–4
):
1
8
. .
25.
Phatak
P
,
Burrows
WM
,
Chesnick
IE
,
Tulapurkar
ME
,
Rao
JN
,
Turner
DJ
,
MiR-199a-3p decreases esophageal cancer cell proliferation by targeting p21 activated kinase 4
.
Oncotarget
.
2018
;
9
(
47
):
28391
407
.
26.
Xu
C
,
Zhu
LX
,
Sun
DM
,
Yao
H
,
Han
DX
.
Regulatory mechanism of lncRNA NORAD on proliferation and invasion of ovarian cancer cells through miR-199a-3p
.
Eur Rev Med Pharmacol Sci
.
2020
;
24
(
4
):
1672
81
. .
27.
Bartel
DP
.
MicroRNAs: target recognition and regulatory functions
.
Cell
.
2009
;
136
(
2
):
215
33
. .
28.
Burchert
A
,
Wang
Y
,
Cai
D
,
von Bubnoff
N
,
Paschka
P
,
Müller-Brüsselbach
S
,
Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development
.
Leukemia
.
2005
;
19
(
10
):
1774
82
.
29.
Li
YL
,
Tang
JM
,
Chen
XY
,
Luo
B
,
Liang
GH
,
Qu
Q
,
MicroRNA-153-3p enhances the sensitivity of chronic myeloid leukemia cells to imatinib by inhibiting B-cell lymphoma-2-mediated autophagy
.
Hum Cell
.
2020
;
33
(
3
):
610
8
.
30.
Hershkovitz-Rokah
O
,
Modai
S
,
Pasmanik-Chor
M
,
Toren
A
,
Shomron
N
,
Raanani
P
,
MiR-30e induces apoptosis and sensitizes K562 cells to imatinib treatment via regulation of the BCR-ABL protein
.
Cancer Lett
.
2015
;
356
(
2 Pt B
):
597
605
.
31.
Jiang
X
,
Cheng
Y
,
Hu
C
,
Zhang
A
,
Ren
Y
,
Xu
X
.
MicroRNA-221 sensitizes chronic myeloid leukemia cells to imatinib by targeting STAT5
.
Leuk Lymphoma
.
2019
;
60
(
7
):
1709
20
. .
32.
Joo
LJS
,
Weiss
J
,
Gill
AJ
,
Clifton-Bligh
R
,
Brahmbhatt
H
,
MacDiarmid
JA
,
RET kinase-regulated microRNA-153-3p improves therapeutic efficacy in medullary thyroid carcinoma
.
Thyroid
.
2019
;
29
(
6
):
830
44
.
33.
Gao
X
,
Wang
X
,
He
H
,
Cao
Y
.
LINC02308 promotes the progression of glioma through activating mTOR/AKT-signaling pathway by targeting miR-30e-3p/TM4SF1 axis
.
Cell Biol Toxicol
.
2021
. .
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.